Could mitochondria play a role in the pathogenesis of Sjogrens disease?! #Eular2023 https://t.co/XndW4qFf3E

Malt lymphoma in Sjogrens disease and role of PET scan. When is PET scan suggestive? Follow: Complement RF Focus score SPEP #Eular2023 https://t.co/60l8iRNvQN

Just a reminder: nr-axSpA isn’t destined to become r-axSpA/AS. Life is more complicated than that. Between the natural history and TNFi, very small conversion rate post-10y. Of course, whatever the x-rays, it can still disable though DESIR cohort POS0675 #EULAR2023 @RheumNow https://t.co/29HeJXpK2S

Very early days, but it’s cool to see transcriptomics in GCA ➡️ in situ spatial profiling ➡️ drug-gene interactions ➡️ new therapeutic targets identified. Only time will tell if they will work, but very cool nevertheless. POS0091 (Mayo, La Jolla, & INSERM) #EULAR2023 @RheumNow https://t.co/n7raIENVOT

I’ve been hearing the term ´Jackies’ used in talks on Jak inhibitors. A shorter form of JAKinibs or JAKi #EULAR2023 @RheumNow

In Brazil, if you’re in the early RA clinic (yellow bars) you do a lot better than other academic clinics, even w bDMARD access. Maybe it’s early Rx, or love & care, or other patient factors - but it’s a reminder that RA isn’t a level playing field. POS0055 #EULAR2023 @RheumNow https://t.co/jI2dvuIHWP

The interface between cutaneous lymphoma and lupus panniculitis, characteristic differences and diagnostic algorithm, Eviatar T, #EULAR2023 @RheumNow https://t.co/HRTQWS4Ctq

Do we use too much PNL in GCA (when not using TCZ)? Could we wean quicker? Salvarini group n=22 26w PNL weaning protocol from GiACTA, but no TCZ 10/26 in relapse free remission at 1y Much less PNL, still some steroid AEs Way of the future for some? POS0728 #EULAR2023 @RheumNow https://t.co/qeZHeCi9vq

Tapering pred in RA - this just rings true from everyday clinic life. Some patients just seem to hit a wall at PNL 2.5. Sometimes it’s GC withdrawal arthralgias/tertiary adrenal insufficiency, but often it’s genuine inflammation. I still wonder why? POS0050 #EULAR2023 @RheumNow https://t.co/JBh26VqPuM

#EULAR2023 #POS0120 From Sjogren to SLE. Interim analysis of Phase 2 RCT showed primary endpoint, SRI-4 + ability to sustain pred dose to ≤5 mg/d or ≤ BL from Wk16 to 28 was achieved more in Ianalumab (Bcell depletion & BAFF-R-i) vs PBO (44% vs 9%). Advance to Phase 3 @RheumNow https://t.co/Wg29uj5yqv

Can machine learning help bDMARD selection in RA? Early days limited by the data available, so not great yet, but efforts underway are a good start for an area where we need to do better than our status quo guessing. Watch this space POS0641 #EULAR2023 @RheumNow https://t.co/2j8H40iFWo

You need to see this! Albert with a Left V1 distribution of #shingles is a ‘bot’ who interacts with #rheumatologists at #EULAR2023 ⁦@RheumNow⁩ ⁦@eular_org⁩ #artificial #intelligence https://t.co/gDwzc3NX7v

#EULAR2023 #POS0116 How does Voclosporin fare in #lupus pts with heavy proteinuria (=>2g/day)? Pooled Analyses from Phase 2&3 RCTs showed consistent improvement in renal response regardless of demographics or clinical characteristics. An option this resistant group @RheumNow https://t.co/AmZ0fStJrW

TNFi & Disease activity-guided dose optimization in RA⬇️prog of ADA or ETA daily dose (100%66%50%0%) 10yrs followup in 170pts ⭐️74% tapered until full discontinuation ⭐️Median time to restart 8 mo ⭐️21% never restarted! What's lacking? % of recovery @Rheumnow OP0131 #EULAR23 https://t.co/Ms6lqQ7cWf

Rituximab in RA - do you need to maintain B cell depletion? Well, in this Paris cohort, if you divide up patients by B cell depletion (at time of next infusion) - no diff in efficacy. Bias possible but B cell depletion in RA isn’t the hill to die on POS0636 #EULAR2023 @RheumNow https://t.co/GLdu9YkL7g